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PRODUCT DEVELOPMENT AND PROGRAMATIC IMPLMENTATION OF 
TYPBAR TCV® AND ROTAVAC® VACCINES 
 




TYP TCV® from Bharat Biotech, is the First Typhoid Conjugate Vaccine Prequalified by WHO. It is the first 
typhoid vaccine, clinically proven to be administered to children from 6 months of age to adults and confers long 
term protection against salmonella typhi. 
 
International Health Metrics and Evaluation (IHME) estimates that in 2016, there were approximately 12 million 
cases of typhoid fever resulting in around 130,000 deaths. In most developing countries the cost of a course of 
treatment for typhoid fever ranges from $50 to $5000 for outpatient and inpatient treatments.  
 
TYPBAR TCV® is a result of dedicated product development at Bharat Biotech since 2001, with the strains 
provided by Dr.  John Robbins, where all aspects of the product profile were studied and evaluated in human 
clinical trials. With 5 years of follow up data for seroconversion, TYPBAR TCV® at 25μg / dose has proven long 
term protection for children and adults alike and can be administered to children from 6 months of age   and 
WHO-SAGE recommended the use of typhoid conjugate vaccines for use in infants between 6 and 23 months 
of age and catch up vaccinations for children between 2 and 15 years of age. This recommendation paves the 
way for countries to introduce the vaccine into their immunization programs.  Oxford University conducted a 
human challenge study with TYPBARTCV®, where the subjects were challenged with live S. Typhi proving a 
protective efficacy of 87% against typhoid fever. 
 
Rotavirus is the leading cause of severe diarrhoea and death among children less than five years of age around 
the world. According to a recent study, 37 percent of the 578,000 childhood diarrheal deaths in 2013 were due 
to rotavirus.  
 
Vaccinations are an important part of global public health efforts to meet the Sustainable Developmental Goals 
of UNDP. ROTAVAC® was developed as a result of a multi country - multi partner collaborative model of Team 
science for over 2 decades and has covered all aspects of product development, licensure, and WHO 
prequalification, and represents a true reflection of “Clone to Clinic to Global Access”, resulting in a lifesaving 
product for global populations. The product profile of ROTAVAC® has been optimally designed for the 
developing world by the developing world to aid ease of administration, reduced training requirements, and with 
the lowest cold chain footprint for an oral rotavirus vaccine in the world.  
 
The project to develop ROTAVAC® has resulted in more than 15 international publications in peer reviewed 
journals, including the pivotal phase III publication in Lancet in 2014 proving its comparable efficacy in the 
developing world. ROTAVAC® has 5 global patents, granted in countries such as India, USA, UK, South Africa, 
China, Nigeria, among several others. Product registrations for ROTAVAC® are in process in more than 30 
countries globally. 
 
